Table 1 Clinicopathologic data
Parameter | Group | Tissue (n= 84) | Serum (n= 75) |
|---|---|---|---|
T status | 1 | 27 (32%) | 31 (41%) |
| Â | 2 | 27 (32%) | 22 (29%) |
| Â | 3 | 6 (7%) | 4 (5%) |
| Â | 4 | 24 (29%) | 18 (25%) |
N status | 0 | 35 (42%) | 28 (37%) |
| Â | 1 | 21 (25%) | 15 (20%) |
| Â | 2 | 14 (17%) | 10 (13%) |
| Â | 3 | 13 (15%) | 9 (12%) |
| Â | 4 | 1 (1%) | 13 (18%) |
M status | 0 | 70 (83%) | 4 (5%) |
| Â | 1 | 14 (17%) | 71 (95%) |
ER status | Negative | 25 (30%) | 23 (31%) |
| Â | Positive | 59 (70%) | 52 (69%) |
PR status | Negative | 45 (54%) | 36 (48%) |
| Â | Positive | 39 (46%) | 39 (52%) |
ErbB2 status | Negative | 62 (74%) | 49 (65%) |
| Â | Positive | 22 (26%) | 26 (35%) |
Grade | 1 | 9 (11%) | 14 (19%) |
| Â | 2 | 32 (38%) | 29 (39%) |
| Â | 3 | 43 (51%) | 32 (42%) |
Stage | I | 24 (29%) | 19 (25%) |
| Â | II | 20 (24%) | 14 (19%) |
| Â | III | 27 (32%) | 22 (29%) |
| Â | IV | 13 (15%) | 20 (27%) |
Disease status | Progressive | 29 (35%) | 47 (63%) |
| Â | Nonprogressive | 55 (65%) | 28 (37%) |